Skip to Content

Patients with NHL and CLL in B cell-directed therapies respond poorly to COVID-19 mRNA vaccination

Especially patients with non-Hodgkin lymphomas and chronic lymphocytic leukemia (CLL) who are actively treated with or have received B cell-directed therapies have failed to produce anti-spike antibodies despite full courses of COVID-19 mRNA vaccination. In this MEDtalk, MD Shipra Goel, Infectious diseases, Roswell Park Comprehensive Cancer Center, Buffalo, New York presents updated results of a study looking at factors that may predict adequate response to COVID-19 vaccines.

Shipra Goel

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top